Press
Coverage of the Inference platform from leading publications, media outlets, and our blog.
January 6, 2026
Platform integrates proprietary and public genetic and multi-omic data with cutting-edge AI to transform drug discovery. Inference Agents autonomously execute PhD-level analyses using Model Context Protocol (MCP). Platform now available to pharmaceutical research partners; powers collaborations totaling over $200 million.
January 6, 2026
Variant Bio and Boehringer Ingelheim announce a multi-year research collaboration to discover and validate novel drug targets for cardiorenal and kidney disease. The partnership combines Boehringer Ingelheim's deep therapeutic expertise with Variant Bio's AI-powered Inference platform, integrating proprietary genomic datasets from global populations.
June 24, 2025
In-depth feature from SoftBank Vision Fund on how Variant Bio is mapping differentiated datasets from studies with globally underrepresented populations to accelerate drug development. Covers the journey from field to lab, the Inference platform, benefit-sharing model, and early drug candidates.
June 24, 2025
Announcing publication of the Southern African Blood Regulatory (SABR) resource in Nature Genetics, a comprehensive genomic study of regulatory variation and blood cell traits in three South African populations.
February 4, 2025
With funding from the Gates Foundation, Variant Bio launches a two-year project leveraging the Inference platform and data from global research partnerships to map immune-related genetic variation across underrepresented populations.
January 7, 2025
Variant Bio and Novo Nordisk announce a multi-year discovery alliance to identify novel targets for metabolic disease and obesity. The partnership leverages the Inference platform to uncover therapeutic opportunities from studies with globally underrepresented populations, where unique genetic variants provide insights not available in existing datasets.
Featured on the front page of The New York Times.
April 23, 2024
Evotec and Variant Bio announce a strategic partnership combining Evotec's drug discovery and development capabilities with Variant Bio's Inference platform to identify novel targets for fibrosis. The collaboration aims to advance programs from target discovery through clinical development.
For press inquiries, please contact info@variantbio.com.
For more updates, visit the Variant Bio blog.
Discover how our platform is transforming genomic drug discovery.